NCT00521014View on ClinicalTrials.gov

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

BIOLOGICAL

sargramostim

DRUG

carmustine

DRUG

cytarabine

DRUG

etoposide

DRUG

melphalan

PROCEDURE

autologous hematopoietic stem cell transplantation

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00521014 - GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter